KRAS and cancer: We report here the preclinical evaluation of glecirasib, which efficiently inhibited the growth of a panel of KRAS p.G12C–mutated cancer cells by inducing cell-cycle arrest and apoptosis and showed favorable selectivity against wild-type (WT) KRAS.